Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02881567 · ClinicalTrials.gov registry record · Phase 3
Efficacy and Safety of Daclizumab in Participants With RRMS Switching From Natalizumab
A Phase 3 study, sponsored by Biogen.
- Terminated
- Registry status
- Phase 3
- Development phase
- 41
- Enrollment target
NCT02881567 is a Phase 3 study that was terminated before completion, run by Biogen. The registered enrollment target is 41 participants.
The verdict
NCT02881567, a Phase 3 study, was terminated before completion, sponsored by Biogen.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 41 participants
- Enrollment target
Study Summary
The primary objective of the study is to evaluate the effects of treatment with daclizumab on the proportion of participants relapse-free at 6 months in Relapsing-Remitting Multiple Sclerosis (RRMS) participants, who switched from treatment with natalizumab to daclizumab due to safety concerns. The secondary objectives of this study in this study population are to evaluate the effects of daclizumab on the following: 1) Multiple Sclerosis (MS) relapse activity including the annualized relapse rate (ARR) and the proportion of participants experiencing relapses requiring hospitalization and/or steroid treatment; 2) MS-related outcomes measured using magnetic resonance imaging (MRI); 3) Safety and tolerability in participants previously treated with natalizumab.
Interventions
- DRUG Daclizumab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 41 participants |
| Start Date | 2017-04-18 |
| Est. Completion | 2018-09-12 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02881567
The ClinicalTrials.gov registry entry for NCT02881567 describes a study currently listed as terminated, categorized as Phase 3. The registered enrollment target is 41 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Biogen, which has 334 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Daclizumab is the first listed.
NCT02881567 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02881567 about?
NCT02881567 is a clinical study titled "Efficacy and Safety of Daclizumab in Participants With RRMS Switching From Natalizumab". The primary objective of the study is to evaluate the effects of treatment with daclizumab on the proportion of participants relapse-free at 6 months in Relapsing-Remitting Multiple Sclerosis (RRMS) participants, who switched from treatment with natalizumab to daclizumab due to safety concerns. The ...
What is the current status of trial NCT02881567?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 41 participants. The study started on 2017-04-18. Estimated completion is 2018-09-12.
What interventions are being tested in trial NCT02881567?
The interventions under investigation include: Daclizumab (DRUG).
Who is sponsoring clinical trial NCT02881567?
This trial is sponsored by Biogen, which has 334 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.